Given the limited options of adequate treatments for Parkinson’s disease dementia, and the safety concerns and modest or uncertain efficacy of currently used off-label treatments, the ANAVEX®2-73 (blarcamesine) study results represent a meaningful step forward toward urgently needed treatment for this serious complication of Parkinson’s disease.”
Yes, if we apply and get BTD for PD or PDD, that would be a catalyst. BTD has some significant implications and benefits and is much harder to get than FT because of higher standards. We've already got FT for RS as an example. FT for PDD is pretty likely.
News 
Market Data 
Discover 
